MediWound Ltd. announced on February 25, 2025, the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, a peer-reviewed journal. The study's findings confirm NexoBrid's superiority over the standard of care in pediatric patients with deep thermal burns.
The CIDS Phase III was a multicenter, multinational, randomized, controlled, open-label study conducted across 36 burn centers, randomizing 145 pediatric patients from newborn to eighteen years of age. These results supported the label expansion of NexoBrid for pediatric patients in the E.U. in 2023 and the U.S. in 2024.
The publication reinforces NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients. This validation highlights its significance as a transformative treatment in burn care, preserving healthy tissue and improving outcomes for young patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.